Karyopharm Therapeutics (KPTI) Prices 6.25M Share Common Offering at $24/Sh

Barclays Starts Karyopharm Therapeutics (KPTI) at Overweight

March 4, 2020 4:41 AM EST

Barclays analyst Peter Lawson initiates coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with a Overweight rating and a price target of $30.00.

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $24.68 yesterday.

... More

Pre-Open Stock Movers 03/03: (MITO) (INO) (WIFI) Higher; (CODX) (TLRY) (KPTI) Lower (more...)

March 3, 2020 9:24 AM EST

Today's Pre-Open Stock Movers

Stealth BioTherapeutics (NASDAQ: MITO) 52.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.

Co-Diagnostics (NASDAQ: CODX) 20.3% LOWER; Maxim Group downgraded from Buy to Hold. Coronavirus plays lower.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) 19.4% HIGHER; announced an accelerated timeline for developing its DNA vaccine... More

After-Hours Stock Movers 03/02: (GNW) (IBIO) (GNMK) Higher; (TLRY) (KPTI) (MAXR) Lower (more...)

March 2, 2020 5:58 PM EST

Today's After-Hours Stock Movers

Genworth Financial, Inc. (NYSE: GNW) 16.3% HIGHER; and China Oceanwide Holdings Group Co., Ltd. (Oceanwide) today announced that they have agreed in principle with the New York State Department of Financial Services (NYDFS) on conditions that are expected to facilitate a reapproval by the NYDFS of the proposed acquisition of control by Oceanwide of Genworth's New York-domiciled insurance company, Genworth Life Insurance Company of New York (GLICNY). Genworth has agreed, among other things, to contribute $100 million to GLICNY at the closing of the Oceanwide... More

Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock

March 2, 2020 4:17 PM EST

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to... More

Karyopharm Therapeutics (KPTI) PT Raised to $37 at RBC Capital

March 2, 2020 1:12 PM EST

RBC Capital analyst Brian Abrahams raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $37.00 (from $26.00) while maintaining an Outperform rating.

removing Speculative Risk qualifieradd'l $500M+ out-year sales oppty in earlier-line MM following this morning's positive BOSTON data.... More

Karyopharm Therapeutics (KPTI) PT Raised to $43 at H.C. Wainwright

March 2, 2020 12:13 PM EST

H.C. Wainwright analyst Edward White raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $43.00 (from $40.00) while maintaining a Buy rating.

... More

Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)

March 2, 2020 9:24 AM EST

Today's Pre-Open Stock Movers

Forty Seven, Inc. (Nasdaq: FTSV) 62% HIGHER; Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory... More

Karyopharm Therapeutics (KPTI) PT Raised to $35 at Baird

March 2, 2020 8:29 AM EST

Baird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $35.00 (from $25.00) while maintaining an Outperform rating following better-than-expected BOSTON study data.

The analyst commented, "This morning, Karyopharm announced highly anticipated Phase 3 results from the BOSTON study of... More

Karyopharm Therapeutics (KPTI) Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in PFS in Patients with Multiple Myeloma

March 2, 2020 7:01 AM EST

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS). The median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in... More